The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opening Session Panel Discussion

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Mar

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opening Session Panel Discussion

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden

2026 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

Prostate Cancer: Low Testosterone Levels May Be Associated With Increased Risk of Progression During Surveillance

Stanford Names Leader for Drug Development and Precision Oncology